Lyophilization Explained: Why Peptides Are Freeze-Dried

Open almost any vial of research peptide and you will find a small white plug or loose powder rather than a liquid. That material is the product of lyophilisation, also called freeze-drying. The process removes water while keeping the peptide intact, and it is the main reason peptides can be shipped and stored for months or years. This article explains how it works and what the finished cake tells you.

Why remove the water?

Water is the medium in which most peptide degradation happens. In solution, peptides are exposed to:

• Hydrolysis of the backbone, especially at aspartic acid residues
• Deamidation of asparagine and glutamine
• Oxidation of methionine, cysteine and tryptophan, accelerated by dissolved oxygen
• Microbial growth, if the solution is not sterile
• Aggregation, as molecules move freely and collide

Removing water slows all of these dramatically. A peptide that is stable for days in solution at room temperature can remain within specification for years as a dry solid kept cold. Dry powder is also lighter and less sensitive to temperature excursions during shipping.

Simply evaporating the water with heat would damage many peptides and leave a hard, glassy film that is difficult to redissolve. Lyophilisation avoids heat by removing water as vapour directly from ice.

The physics in one paragraph

Below a certain temperature and pressure (water's triple point, about 0.01 °C and 611 Pa), ice can turn directly into vapour without melting. This is sublimation, the same reason snow slowly disappears on a cold, dry day without forming puddles. A freeze-dryer creates those conditions deliberately: it freezes the solution, then lowers the pressure and supplies just enough heat to drive sublimation, with a very cold condenser trapping the vapour.

The three stages

A lyophilisation run has three distinct stages. Each has its own goal and failure modes.

Stage	Typical conditions	What happens	Water removed
1. Freezing	Shelf cooled to about −40 to −50 °C at atmospheric pressure	Water forms ice crystals; peptide and solutes concentrate between them	None
2. Primary drying	Chamber pressure reduced to roughly 5–20 Pa; shelf warmed gently	Ice sublimes from the top of the cake downward	Around 90–95%
3. Secondary drying	Shelf raised toward 20–40 °C under vacuum	Bound (unfrozen) water desorbs from the solid	Most of the remainder

1. Freezing

The solution is cooled until the water freezes. As ice crystals grow, the peptide, buffer and any excipients are pushed into the spaces between them, forming a concentrated, amorphous (glassy) or partly crystalline phase. The size of the ice crystals matters: they leave behind the pores through which vapour escapes later. Slow freezing tends to give larger crystals and faster drying; some processes add an annealing step, briefly warming the frozen product, to encourage larger, more uniform crystals.

2. Primary drying

The chamber pressure is lowered and the shelves are warmed slightly. Ice sublimes from the surface, and the drying front moves down through the product, leaving a porous structure. This is the longest stage, often many hours or days for large batches.

The critical constraint is product temperature. Each formulation has a collapse temperature, close to the glass transition temperature of the freeze-concentrated phase (written Tg′). If the product warms above it while ice is still present, the porous structure softens and slumps. The process is therefore run just below that limit: warm enough to dry efficiently, cold enough to keep the structure intact.

3. Secondary drying

After the ice has gone, a few percent of water remains bound to the peptide and excipients. Raising the shelf temperature under vacuum drives this water off. Secondary drying sets the final residual moisture of the product. When drying is complete, vials are typically back-filled with dry nitrogen and stoppered inside the chamber, so the dried product never meets humid air.

Reading the cake

The appearance of a lyophilised cake gives useful clues about how the run went, although it is not proof of quality on its own.

• Elegant cake. A uniform, white to off-white plug with an even texture, filling roughly the volume of the original liquid. This is the ideal.
• Shrinkage. A cake that has pulled slightly away from the vial wall. Usually cosmetic and common.
• Cracking or loose powder. Often caused by vibration in transit or by low solid content. Small fill masses, typical of research vials holding a few milligrams, frequently appear as a thin film or fine powder rather than a solid plug. This is normal.
• Collapse or meltback. A shrunken, glassy, yellowish or sticky residue, sometimes with visible bubbles. This indicates the product warmed above its collapse temperature or retained too much water. Collapsed material can have higher moisture and reduced stability.
• Discolouration. Yellow or brown tints can point to oxidation or contamination and are worth asking about.

Because so many research peptides are lyophilised from water or dilute acetic acid without bulking agents, a very small, irregular or barely visible deposit is expected. What matters is the analytical data on the certificate, not how photogenic the cake is.

Residual moisture

Residual moisture is the water left after secondary drying, expressed as a percentage of the cake mass. For peptides it is commonly a few percent, and specifications often set an upper limit such as 5–8% depending on the material. Too much water speeds degradation; for some proteins extreme over-drying is also undesirable, though this is rarely a concern for small peptides.

Moisture is measured by:

• Karl Fischer titration, the reference method, which reacts water quantitatively with iodine (USP ⟨921⟩, Ph. Eur. 2.5.12)
• Loss on drying, simpler but less specific, since any volatile counts
• Near-infrared spectroscopy, non-destructive and usable through the vial glass

Lyophilised peptides are also hygroscopic: they absorb moisture from air. That is why the standard advice is to let a cold vial reach room temperature before opening it, so condensation does not form on the powder.

Excipients and the role of counter-ions

Pharmaceutical lyophilised products often contain excipients: bulking agents such as mannitol to give a robust cake, and sugars such as sucrose or trehalose to protect the molecule's structure. Research peptides are usually supplied without them, as the peptide plus its counter-ion (TFA, acetate or chloride) and bound water. These non-peptide components are why net peptide content is below 100% even for very pure material.

What this means for researchers

1. Lyophilised peptides are stable mainly because water has been removed; keeping them dry and cold preserves that advantage.
2. Cake appearance varies widely with fill mass and formulation; judge quality by the certificate.
3. A collapsed, sticky or discoloured residue is worth querying with the supplier.
4. Once reconstituted, a peptide behaves like any solution and loses the stability benefits of the dry state.

For practical guidance on handling lyophilised material after delivery, see reconstitution and storage of lyophilised peptides.

References

• Franks F. Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm. 1998;45(3):221–229.
• Tang X, Pikal MJ. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21(2):191–200.
• Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res. 1997;14(8):969–975.
• Rey L, May JC, eds. Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products. 3rd ed. Informa Healthcare; 2010.
• United States Pharmacopeia. General Chapter ⟨921⟩ Water Determination. USP–NF.
• European Pharmacopoeia. 2.5.12 Water: Semi-Micro Determination.